News | July 22, 2023
Lonza delivers 5.6% CER sales growth and 30% CORE EBITDA margin
Good momentum in commercial CDMO business
Good momentum in commercial CDMO business
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
CMOs showed an increasing reluctance to take on debt in 2022
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
The newly launched Genomic Health Insights (GHI) program to make sequencing accessible to all
The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
OncoVeryx-F, a proprietary test developed by PredOmix, is set to transform early-stage cancer detection
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
Subscribe To Our Newsletter & Stay Updated
